About: C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im Jahr 2005 veröffentlichter wissenschaftlicher Artikel (de) article scientifique (publié 2005) (fr) наукова стаття, опублікована в січні 2005 (uk) artículu científicu espublizáu en xineru de 2005 (ast) artikull shkencor i botuar më 01 janar 2005 (sq) scientific article published on 01 January 2005 (en)
publication date	wds:Q81248096-0E58DC26-5653-495E-8919-D99DA6DC138C
publication date	2005-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q81248096-2AAABEFA-45CA-4355-B8AA-5D512AE0B89D wds:Q81248096-8E2D06A3-51FC-4389-A548-281527DE0B57 wds:Q81248096-CF8E7DAE-51D9-4710-B2A0-648089BA5298 wds:Q81248096-DAF53F92-5567-421E-8B54-A3E3C6F6E9C5 wds:Q81248096-E8096279-2EB0-45DA-BDDF-3F2D40CCE93A wds:Q81248096-FE37D6EC-3C44-43B2-989C-4BBA38DD3A9A
author name string	Yohei Seto Victoria Bejarano Maya H Buch Sarah J Bingham Jo White Domini Bryer
rdfs:label	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (en) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (nl) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (sq)
skos:prefLabel	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (en) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (nl) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (sq)
name	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (en) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (nl) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (sq)
author	wds:Q81248096-9F5B419F-8D2B-42FE-BDED-6C6D74ED93AB
author	Paul Emery
title	wds:Q81248096-17E68D05-11CD-4B56-ACB0-1E771ADF0F42
title	C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept (en)
page(s)	wds:Q81248096-FC98A8B7-00E5-47D8-9BDA-32A0B202AF5D
page(s)	42-48
instance of	wds:Q81248096-144D30A9-A114-4B95-87AB-C243EF55B8BC
instance of	scholarly article
main subject	wds:Q81248096-D2EB8496-908B-4F40-8823-60F8E3650B77
main subject	rheumatoid arthritis
PubMed ID	wds:Q81248096-FAA1160D-B478-4EC1-B2D4-5EDA4B3C7FB4
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15641046
PubMed ID	15641046
published in	wds:Q81248096-C567B466-7797-4C9D-971E-7515A8A20A23
published in	Arthritis and Rheumatism
issue	wds:Q81248096-6AEE7B02-2E21-4DC3-B55F-7BAB1C40B35B
volume	wds:Q81248096-BCA79C54-0502-484A-BF31-B1BB140282DD
issue	1
volume	52
DOI	wds:Q81248096-56CF8F1B-C5C8-433B-8008-68583B8BEB14
DOI	http://dx.doi.org/10.1002/ART.20711
DOI	10.1002/ART.20711
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81248096
is cites work of	Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFα therapy in rheumatoid arthritis? The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis Biologic therapies in rheumatology: lessons learned, future directions Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 New therapies for treatment of rheumatoid arthritis Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Biomarkers for rheumatoid arthritis: making it personal The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis Treatment of rheumatoid arthritis. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment? Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis. The role of biomarkers in the management of patients with rheumatoid arthritis The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
is cites work of	wds:Q35760136-8B8C935A-7589-4A64-8F1F-99ACB5D6EE75 wds:Q34315535-3B905669-C7B1-4E17-9C5B-83FF443EF1DF wds:Q36849874-5FE5566C-ED03-4015-ADF4-01B8C0AA4483 wds:Q81445112-24956B13-E45E-4E06-A2C2-0B3E5D476A88 wds:Q59650804-E532664D-D4AD-46C5-B929-72AADF3EFB5C wds:Q35336802-D65E2447-221F-48BD-8A03-0D5331EC6C8D wds:Q90457374-4CEB209E-9DB4-4C4B-9FA7-92EB13DFBC19 wds:Q34588629-B287F931-4817-4144-ABCA-7CA5D8EEEB7E wds:Q35638252-C70AC658-3437-498C-A376-A3B6B0E253E3 wds:Q41556413-515C9AAA-DFD5-42FE-BD48-EB9A04CC909A wds:Q37270792-006D84C4-9570-40FA-893C-D34AE3931251 wds:Q37601582-C6296F5B-E164-49AD-A2F4-9D5C39ECCD4E wds:Q36171750-49A28B8C-9FFD-4908-8086-C9517E72B61D wds:Q52855355-284D35C8-B9BF-43A7-9AC2-A74CD02B94D9 wds:Q37572857-62E51181-8792-4157-8C1A-9390AB9631C1 wds:Q34604437-EB3C96CF-79F3-4A14-B3DD-C0EE01291398 wds:Q33750084-E9C8DE6F-AC4E-46C7-B47C-8D79B5F734BA wds:Q36823811-66B3E28B-2408-4C35-8848-3ECFA796808C

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software